About this trial
Some of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)/ventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF/VT. In 2022, one prospective cluster randomized trial showed increased survival among (OHCA) patients in refractory VF using Double Sequential Defibrillation (DSD). If DSD can increase survival among all patients in VF that dont respond to one defibrillation, i.e. before it has become refractory is not known.
The aim of this trial is to assess survival with a double defibrillation strategy initiated as soon as possible among patients with Out of Hospital Cardiac Arrest with initial shockable rhythm and at least one failed standard defibrillation, compared with continued resuscitation using standard defibrillation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
OHCA patients with VT/VF at first rhythm analysis and at least one defibrillation performed in standard (A-L) position
Disqualifiers
Age < 18 years
Obvious pregnancy
Known preexisting Do Not Attempt Resuscitation order
Trial design
Parallel
Treatments tested in this trial
Double sequential defibirllation
DeviceA second defibrillator will be applyed with electrodes placed in the A-P position and defibrillation will be performed with two defibrllators in a sequential manner
Standard defibrillation
DeviceStandard defibrillation uning one defibrillator
Treatment groups
Trial outcomes
Primary outcomes
30 day survival
Survival at 30 days
Secondary outcomes
ROSC
Any prehospital ROSC, defined as confirmed ROSC by EMS personnel, in accordance with latest Utstein definition
Survival to hospital Admission
Admitted alive to a hospital ward with spontaneous circulation
Survival to hospital discharge
Discharged alive from hospital
Neurological function at hospital discharge, mRS (modified Ranking scale, 1-6 where 1 indicates better function)
Neurological function at hospital discharge (mRS)
Other outcomes
90 days survival
Survival to 90 days
Neurological function at 90 days (mRS)
Neurological function at 90 days (modified Ranking scale)
Helath related quality of life at 90 days
Helath related quality of life at 90 days
Neurological function at 180 days (mRS)
Neurological function (modified Ranking Scale)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Gabriel Riva
Lead sponsor
Karolinska Institutet
Sponsor institution
Swedish Heart Lung Foundation
Collaborator
Region Stockholm
Collaborator
Vastra Gotaland Region
Collaborator
Region Halland
Collaborator
Laerdal Foundation
Collaborator